vs
Side-by-side financial comparison of Xiao-I Corp (AIXI) and Autolus Therapeutics plc (AUTL). Click either name above to swap in a different company.
Autolus Therapeutics plc is the larger business by last-quarter revenue ($21.2M vs $11.5M, roughly 1.8× Xiao-I Corp). Xiao-I Corp runs the higher net margin — -263.9% vs -373.3%, a 109.4% gap on every dollar of revenue.
Xiao-i is a Chinese cognitive artificial intelligence enterprise founded in 2001.
Autolus Therapeutics plc is a clinical-stage biopharmaceutical company specializing in the development of next-generation engineered chimeric antigen receptor T-cell (CAR-T) therapies for the treatment of hematological malignancies and solid tumors. It operates in the global oncology biotech market, advancing a pipeline of targeted immunotherapy candidates across multiple clinical development stages.
AIXI vs AUTL — Head-to-Head
Income Statement — Q2 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $11.5M | $21.2M |
| Net Profit | $-30.4M | $-79.1M |
| Gross Margin | 58.1% | — |
| Operating Margin | -254.9% | -337.9% |
| Net Margin | -263.9% | -373.3% |
| Revenue YoY | — | — |
| Net Profit YoY | — | 3.6% |
| EPS (diluted) | — | $-0.30 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | — | $21.2M | ||
| Q2 25 | $11.5M | $20.9M | ||
| Q1 25 | — | $9.0M | ||
| Q3 24 | — | $0 | ||
| Q2 24 | $33.0M | $0 | ||
| Q1 24 | — | $10.1M | ||
| Q2 23 | $26.5M | — |
| Q3 25 | — | $-79.1M | ||
| Q2 25 | $-30.4M | $-47.9M | ||
| Q1 25 | — | $-70.2M | ||
| Q3 24 | — | $-82.1M | ||
| Q2 24 | $-15.5M | $-58.3M | ||
| Q1 24 | — | $-52.7M | ||
| Q2 23 | $-18.8M | — |
| Q3 25 | — | — | ||
| Q2 25 | 58.1% | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 64.5% | — | ||
| Q1 24 | — | — | ||
| Q2 23 | 77.3% | — |
| Q3 25 | — | -337.9% | ||
| Q2 25 | -254.9% | -292.6% | ||
| Q1 25 | — | -726.3% | ||
| Q3 24 | — | — | ||
| Q2 24 | -45.0% | — | ||
| Q1 24 | — | -384.1% | ||
| Q2 23 | -51.5% | — |
| Q3 25 | — | -373.3% | ||
| Q2 25 | -263.9% | -229.0% | ||
| Q1 25 | — | -781.1% | ||
| Q3 24 | — | — | ||
| Q2 24 | -47.2% | — | ||
| Q1 24 | — | -522.1% | ||
| Q2 23 | -70.9% | — |
| Q3 25 | — | $-0.30 | ||
| Q2 25 | — | $-0.18 | ||
| Q1 25 | — | $-0.26 | ||
| Q3 24 | — | $-0.31 | ||
| Q2 24 | $-0.64 | $-0.22 | ||
| Q1 24 | — | $-0.24 | ||
| Q2 23 | $-0.80 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $5.0M | $86.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $265.5M |
| Total Assets | $82.4M | $661.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $86.1M | ||
| Q2 25 | $5.0M | $123.8M | ||
| Q1 25 | — | $95.8M | ||
| Q3 24 | — | $657.1M | ||
| Q2 24 | $1.8M | $705.9M | ||
| Q1 24 | — | $758.5M | ||
| Q2 23 | $4.7M | — |
| Q3 25 | — | $265.5M | ||
| Q2 25 | — | $346.5M | ||
| Q1 25 | — | $371.1M | ||
| Q3 24 | — | $477.0M | ||
| Q2 24 | — | $527.8M | ||
| Q1 24 | — | $582.0M | ||
| Q2 23 | $525.1K | — |
| Q3 25 | — | $661.9M | ||
| Q2 25 | $82.4M | $721.0M | ||
| Q1 25 | — | $746.3M | ||
| Q3 24 | — | $827.5M | ||
| Q2 24 | $87.6M | $853.6M | ||
| Q1 24 | — | $901.4M | ||
| Q2 23 | $51.3M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.3M | $-67.9M |
| Free Cash FlowOCF − Capex | — | $-72.3M |
| FCF MarginFCF / Revenue | — | -341.2% |
| Capex IntensityCapex / Revenue | — | 20.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-322.5M |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $-67.9M | ||
| Q2 25 | $-2.3M | $-72.8M | ||
| Q1 25 | — | $-75.6M | ||
| Q3 24 | — | $-76.7M | ||
| Q2 24 | — | $-51.1M | ||
| Q1 24 | — | $-40.5M | ||
| Q2 23 | — | — |
| Q3 25 | — | $-72.3M | ||
| Q2 25 | — | $-80.1M | ||
| Q1 25 | — | $-83.8M | ||
| Q3 24 | — | $-86.3M | ||
| Q2 24 | — | $-51.9M | ||
| Q1 24 | — | $-41.0M | ||
| Q2 23 | — | — |
| Q3 25 | — | -341.2% | ||
| Q2 25 | — | -382.6% | ||
| Q1 25 | — | -933.1% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -406.8% | ||
| Q2 23 | — | — |
| Q3 25 | — | 20.8% | ||
| Q2 25 | — | 34.8% | ||
| Q1 25 | — | 91.8% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 5.3% | ||
| Q2 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
